ALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys
Home News ALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys

ALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys

DECEMBER 4, 2023 BHH Members Initiatives

ALLOX, a techbio company developing a proprietary technology to design new drugs targeting allosteric sites within oncology and other diseases, announces its incorporation today, as well as the successful closing of an undisclosed pre-seed financing from Asabys’ new fund Sabadell Asabys II.

ALLOX is a spin-off from the Centre for Genomic Regulation (CRG) in Barcelona, and is co-founded by Ben Lehner, Júlia Domingo, Pablo Baeza and Andre Faure. The company, with lab and office at the CRG/PRBB, has a unique systematic and scalable platform which can map allosteric sites in a large amount of proteins, including ‘undruggable’ or hard-to-target therapeutic targets.

Proteins are the effectors of molecular life. They interact with each other and the disruption of these interactions (so-called active sites) has been the main way of developing many of the current drugs on the market. Since nature is smart and highly resource-efficient, often these active sites are conserved in several proteins, which represents a drawback when you are trying to target a particular one. Often, targeting these interactions can have both a therapeutic and toxic effect, the main reason why many drugs never reach patients.

Lately, the search of selectivity has been fruitful thanks to the development of allosteric modulators. The term allostery means “other sites”. Allosteric sites are protein pockets, in which a molecule can bind, affecting the protein shape and indirectly blocking the protein-protein interactions that need to be targeted. Allosteric sites, in comparison with active ones, are often non-conserved and specific to each protein, so ensuring selectivity and safety. A holy grail for drug developers.

Yet, protein allosteric sites can be tough to find, and often very costly and time demanding. Many approaches have been developed computationally, very few experimentally, and almost none combining both experimental and computational ones, as ALLOX.

The ALLOX platform is based on ‘multidimensional mutagenesis’, an experimental method that allows measuring the activity of as many as 1 million mutant versions of a protein in a single experiment. The method is able to directly link genetic changes to phenotypical and finally biophysical measurements, which is something unprecedented. It is a tool for picking a needle in a haystack. This method allows to scan through, at the protein sequence level, and identify new allosteric pockets. Differently from other methodology, it is scalable, quick and cost efficient.

This financing by Sabadell Asabys will allow ALLOX to establish the initial team and facilities and to reach the level of validation and data that should trigger a new financial round in 18 to 24 months from now.

Asabys has successfully backed several other spin-offs and early-stage companies such as Ona Therapeutics, Origo Biopharma, SpliceBio, Inbrain Neuroelectronics, Nuage Therapeutics and OrikineBio.

Júlia Domingo, co-founder and CEO of ALLOX, comments: “A large portion of the therapeutic space is currently considered undruggable. Overcoming this challenge requires creating innovative and more intelligent therapeutics. ALLOX was founded with this mission in mind, convinced that the integration of massive high-throughput screening with AI will accelerate and revolutionise drug discovery. We feel fortunate and proud to embark on this exciting journey with Asabys.”

Ben Lehner, co-founder of ALLOX, adds: “I’m really happy that we have been able to found this company in Barcelona, the city in which this technology was developed. When we started this project it was pure blue skies research with no application. It was only much later that we realised the potential for drug development. It’s really exciting to see real world applications of our research. It’s also really interesting that there are now seven spin-out companies form the CRG and all seven of them have their foundations in basic non-translational research in genomics and computational biology. This blue skies research on foundational problems is where real innovation and new technology comes from.”

Clara Campàs, Managing Partner at Asabys, mentions “ALLOX’s outstanding technology and team have the potential to revolutionize the way we design and discover new and better medicines. We look forward to continuing working side by side with the founders to bring such innovation to patients”.

October 15, 2024 BHH Members Initiatives
Discover how Robopedics is shaping the future of dependent care
From home assistance robots to sensors to the next level.
Read more
October 14, 2024 BHH Members Initiatives
Scilife Showcase - Quality First: How to reduce deviations and cultivate a quality-driven environment
Join live Scilife Showcase 'Quality First: How to reduce deviations and cultivate a quality-driven environment with Scilife' on October 24th.
Read more
October 08, 2024 BHH Members Initiatives
How to Open Your Business in Spain: A Comprehensive Guide By Entre Trámites
Here's a complete guide to help you begin your entrepreneurial journey in Spain.
Read more
October 08, 2024 BHH Members Initiatives
Apply to the eighth edition of the Fundación MAPFRE Awards for Social Innovation
This initiative arises from the intention to support innovative solutions that have the potential to make a major social impact.
Read more
October 07, 2024 BHH Members Initiatives
AI based solutions and advanced digital technologies to revolutionise stroke care in Europe
UMBRELLA, a consortium of over 20 public and private partners co-led by Vall d’Hebron Research Institute (VHIR) and Siemens Healthineers kicks off with the aim of revolutionising the entire stroke care pathway in Europe.
Read more
October 03, 2024 BHH Members Initiatives
Angelini Pharma celebrates 40 years of eye healthcare with innovative new solutions for glaucoma side effects
The company reaffirms its commitment to ophthalmology with the launch of a solution designed to mitigate the side effects associated with the management of this disease.
Read more
September 30, 2024 BHH Members Initiatives
Revolutionizing remote work with multilingual talent at competitive costs
Remoters offers a crucial differentiating advantage: multilingual professionals at highly competitive prices.
Read more
September 27, 2024 BHH Members Initiatives
Meet BHH provider Roberta Giannini
Roberta’s expertise lies in identifying new business opportunities and designing custom solutions that align with market trends and customer needs.
Read more
September 27, 2024 BHH Members Initiatives
Recruit experienced students from Master’s Degree in Health Data Science (MHEDAS) for internships
BHH partner Universitat Rovira i Virgili (URV)/EIT Health is calling out for companies, research centers, hospitals and institutions to host internships for the students of their Master’s Degree in Health Data Science (MHEDAS).
Read more
September 26, 2024 BHH Members Initiatives
Asabys announces the closing of €180M oversubscribed Sabadell Asabys II Fund
Similar to Sabadell Asabys Fund I, the Fund II portfolio will include companies within the fields of biopharma, medtech and digital health that provide a clear benefit for patients.
Read more